No connection

Search Results

BDX vs ELV

BDX
Becton, Dickinson and Company
NEUTRAL
Price
$156.41
Market Cap
$56.67B
Sector
Healthcare
AI Confidence
90%
ELV
Elevance Health, Inc.
NEUTRAL
Price
$328.11
Market Cap
$72.42B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BDX
25.56
ELV
13.02
Forward P/E
BDX
11.57
ELV
11.29
P/B Ratio
BDX
1.76
ELV
1.65
P/S Ratio
BDX
2.58
ELV
0.36
EV/EBITDA
BDX
10.52
ELV
7.65

Profitability

Gross Margin
BDX
46.78%
ELV
25.56%
Operating Margin
BDX
13.35%
ELV
1.54%
Profit Margin
BDX
8.01%
ELV
2.84%
ROE
BDX
6.96%
ELV
13.25%
ROA
BDX
4.08%
ELV
4.35%

Growth

Revenue Growth
BDX
1.6%
ELV
9.5%
Earnings Growth
BDX
28.6%
ELV
36.3%

Financial Health

Debt/Equity
BDX
0.77
ELV
0.74
Current Ratio
BDX
1.05
ELV
1.53
Quick Ratio
BDX
0.37
ELV
1.41

Dividends

Dividend Yield
BDX
2.67%
ELV
2.15%
Payout Ratio
BDX
68.14%
ELV
27.13%

AI Verdict

BDX NEUTRAL

BDX shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.

Strengths
Company has established market presence
Risks
Limited historical data available for full assessment
ELV NEUTRAL

Elevance Health presents a complex value proposition characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health. While the stock is objectively undervalued, trading below its Graham Number ($340.31) and significantly below its intrinsic value ($763.75), recent financial performance is concerning with a -44.8% Q/Q EPS decline. The combination of bearish technicals and insider selling offsets the attractive valuation and strong analyst buy ratings. Consequently, the stock appears to be in a transition phase where deep value meets fundamental weakness.

Strengths
Trading below Graham Number ($340.31), suggesting defensive undervaluation
Low P/E ratio (13.02) and Forward P/E (11.29) relative to historical norms
Sustainable dividend profile with a low payout ratio of 27.13%
Risks
Weak fundamental health as evidenced by a Piotroski F-Score of 3/9
Sharp recent decline in earnings growth (-44.8% Q/Q EPS growth)
Bearish technical trend (0/100) and negative 1-year price performance (-17.6%)

Compare Another Pair

BDX vs ELV: Head-to-Head Comparison

This page compares Becton, Dickinson and Company (BDX) and Elevance Health, Inc. (ELV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile